Brustugun Odd Terje, Helland Åslaug, Fjellbirkeland Lars, Kleinberg Lilach, Ariansen Sarah, Jebsen Peter, Scott Helge, Dønnem Tom, Bremnes Roy, Berg Thomas, Grønberg Bjørn Henning, Dai Hong Yan, Wahl Sissel Gyrid Freim, Mangseth Kjersti, Helgeland Lars
Avdeling for kreftbehandling, Oslo universitetssykehus, Radiumhospitalet, Norway.
Tidsskr Nor Laegeforen. 2012 Apr 30;132(8):952-5. doi: 10.4045/tidsskr.11.1017.
Epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) are a relatively new class of drugs for treatment of non-small-cell lung cancer. The national professional group for lung cancer, The Norwegian Lung Cancer Group, recommends that patients with non-small-cell lung cancer are tested for mutations in the EGFR gene. Here, we report the experience collected after the introduction of such testing in Norway in 2010.
Information on the number of patients tested, gender distribution, histopathological data and analysis results have been collected from the molecular-pathology laboratories at the university hospitals in Tromsø, Trondheim, Bergen and Oslo for the period from May 2010 to May 2011.
During this period, altogether 1,058 patients with lung cancer were tested for mutations in the EGFR gene, equal to approximately half of all those who were diagnosed with non-small-cell lung cancer. A mutation was detected in 123 patients (11.6 per cent). There was a higher proportion of mutation-positive women than men (17.6 per cent, compared to 6.3 per cent, p < 0.001), and a lower proportion with squamous cell carcinoma than for other histopathological subtypes (3.0 per cent, compared to 12.9 per cent, p < 0.001). Of a total of 80 cytological tests, nine (11.3 per cent) were positive.
In light of the relatively high mutation frequency and a considerable number of positives in the group with squamous cell carcinoma, we recommend to continue the practice of mutation-testing all patients with non-small-cell lung cancer.
表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（EGFR-TKI）是一类相对较新的用于治疗非小细胞肺癌的药物。挪威肺癌国家专业组织挪威肺癌小组建议对非小细胞肺癌患者进行EGFR基因突变检测。在此，我们报告2010年挪威引入此类检测后收集的经验。
收集了2010年5月至2011年5月期间特罗姆瑟、特隆赫姆、卑尔根和奥斯陆大学医院分子病理实验室关于检测患者数量、性别分布、组织病理学数据及分析结果的信息。
在此期间，共对1058例肺癌患者进行了EGFR基因突变检测，约占所有确诊非小细胞肺癌患者的一半。123例患者（11.6%）检测到突变。突变阳性女性比例高于男性（分别为17.6%和6.3%，p<0.001），鳞状细胞癌患者的突变比例低于其他组织病理学亚型（分别为3.0%和12.9%，p<0.001）。在总共80例细胞学检测中，9例（11.3%）呈阳性。
鉴于相对较高的突变频率以及鳞状细胞癌组中有相当数量的阳性病例，我们建议继续对所有非小细胞肺癌患者进行突变检测。
